BridgeBio Pharma, Inc.

AI-generated fair value estimate for this company.

Method: Sum-of-the-parts. (1) DCF on the in-market Attruby/Beyonttra (acoramidis) ATTR-CM franchise: revenue $950M (2026) growing to a $3.25B peak (2031-32) then tapering to $3.05B by 2035; FCF margin ramps from 5% (2026) to a 37-41% terminal range; discounted at 10% WACC with 2% terminal growth, EV ~$10.81B. (2) Probability-of-success-weighted rNPV for three near-term pipeline assets discounted at 12%: BBP-418/LGMD2I (~$578M risked NPV, 85% POS, PDUFA 11/27/2026), encaleret/ADH1 (~$384M, 85% POS, PDUFA 5/8/2027), oral infigratinib/achondroplasia (~$611M, 80% POS); pipeline total ~$1.57B. Combined EV ~$12.39B, less net debt ~$2.63B, equity value ~$9.75B / 195.49M diluted shares.

Reasoning: BBIO is only about a year into its Attruby launch with two more FDA decisions inside 12 months plus a third filed asset, so splitting an in-market-product DCF from probability-weighted rNPVs for pre-approval assets is the standard rigorous biopharma approach rather than a single blended DCF or a trailing-revenue multiple.